Nasser Altorki, MD / Jonathan D. Spicer, MD, PhD, FRCSC - Can the Addition of Immunotherapy to Multimodal Management of Stage I-III NSCLC Help Break the Stalled Cycle of Poor Outcomes?

Go online to PeerView.com/CRA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to the early-stage setting and transforming the multimodal management of resectable stage I-III NSCLC. While remarkable data have emerged from several trials assessing ICIs and rational combinations in neoadjuvant and/or adjuvant settings, many questions remain. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal timing and duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? These and other essential topics are addressed by two leading experts in thoracic surgery in this PeerView Live Seminar and Case Forum. Watch this stimulating discussion of practice-changing data on perioperative immunotherapy, surgical implications and applicability to practice, and how to make the most of ICIs as part of multimodal management of resectable NSCLC to reduce the risk of recurrence and improve cure rates. You will also be able to watch an intriguing debate of real cases selected to highlight the practicalities and challenges of integrating perioperative immunotherapy into practice. Upon completion of this CE activity, participants will be able to: Review the mechanistic aspects of immune checkpoint inhibition, rationale for their use as a component of multimodal therapy in earlier stages of lung cancer, and key clinical trials evaluating immunotherapies in these settings, Describe the latest evidence on surrogate endpoints, such as pathologic response criteria, to assess treatment response and gain perspective on the prognosis of patients with resectable lung cancer receiving immunotherapy, Select appropriate resectable NSCLC patients for perioperative immunotherapy, weighing the benefits/limitations and surgical implications based on critical analysis of clinical trial findings and persisting misperceptions, Implement best practices for multidisciplinary communication and collaboration to ensure integration of immunotherapies into multimodal treatment plans for appropriate patients with stage I-III resectable NSCLC.